Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma

Urology

Volumn 54, Issue 3, 1999, Pages 479-485

  Gettman, Matthew T ^a   Pacelli, Anna ^a   Slezak, Jeff ^a   Bergstralh, Erik J ^a   Blute, Michael ^a   Zincke, Horst ^a   Bostwick, David G ^a,b  

^a MAYO CLINIC   (United States)

^b BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; DNA DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN ANALYSIS; SEMINAL VESICLE;

ADENOCARCINOMA; ADULT; FOLLOW-UP STUDIES; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032856037     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00202-2     Document Type: Article

References (29)

1. Zincke H, Utz DC, and Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199-1205, 1986.
2. Lowe BA, and Lieberman SF: Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 158: 1452-1456, 1997.
3. Lerner SE, Blute ML, and Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154: 1447-1452, 1995.
4. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830, 1994.
5. Catalona WJ, and Smith AJ: Staging errors in clinically localized prostatic cancer. J Urol 147: 452-456, 1992.
6. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
7. Nativ O, Winkler HZ, Raz Y, et al: Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc 64: 911-919, 1989.
8. Cheng WS, Frydenberg M, Bergstralh EJ, et al: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42: 283-291, 1993.
9. Hawkins CA, Bergstralh EJ, Lieber MM, et al: Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 prostate cancer after radical retropubic prostatectomy. Urology 46: 356-364, 1995.
10. Zeitman AL, Edelstein RA, Coen JJ, et al: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43: 828-833, 1994.
11. Morgan WR, Zincke H, Rainwater LM, et al: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). J Urol 145: 319-323, 1991.
12. Epstein JI, Carmichael M, and Walsh PC: Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade, and margins of resection to prognosis. J Urol 149: 1040-1045, 1993.
13. Kausik SJ, Blute ML, Bergstralh EJ, et al: Evaluation of positive margins in limited extracapsular prostate cancer and its impact on outcome after radical prostatectomy. J Urol 159: 1143A, 1998.
14. Amling CL, Bergstralh EJ, Blute ML, et al: Prostate cancer progression rates following radical prostatectomy in patients with seminal vesicle involvement. J Urol 159: 493A, 1998.
15. Blute ML, Bostwick DG, Seay TM, et al: Pathologic classification of prostate carcinoma - the impact of margin status. Cancer 82: 902-908, 1998.
16. Weidner N, Carroll P, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-407, 1993.
17. Brawer MK, Deering RE, Brown M, et al: Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 73: 678-687, 1994.
18. Brawer MK: Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma. Cancer 78: 345-349, 1996.
19. Silberman MA, Partin AW, Veltri RW, et al: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997.
20. Hall MC, Troncoso P, Pollack A, et al: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44: 869-875, 1994.
21. Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48:47-57, 1996.
22. Andrawis RI, Nashid NS, Lindquist RR, et al: Angiogenesis in prostate cancer and benign prostatic hyperplasia. J Urol 155: 353A, 1996.
23. Velendzas DG, Wang JP, Droller M, et al: Microvessel density in benign prostatic hyperplasia, high grade prostatic intraepithelial neoplasia and prostate cancer. J Urol 155: 554A, 1996.
24. Gettman MT, Bergstralh EJ, Blute M, et al: Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 51: 79-85, 1998.
25. Sakr WA, Wheeler TM, Blute M, et al: Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer 78: 366-368, 1996.
26. Grignon DJ, and Sakr WA: Pathologic staging of prostate carcinoma - what are the issues? Cancer 78: 337-340, 1996.
27. Bostwick DG: Staging prostate cancer - 1997: current methods and limitations. Eur Urol 32: 2-14, 1997.
28. Bostwick DG, Myers RP, and Oesterling JE: Staging of prostate cancer. Semin Surg Oncol 10: 60-72, 1994.
29. Klee GG, Dodge LA, Zincke H, et al: Measurement of serum prostatic specific antigen using ImX prostate specific antigen assay. J Urol 151: 94-98, 1994.